Chemistry:Bemcentinib
 | |
| Clinical data | |
|---|---|
| Other names | BGB324; R428 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C30H34N8 |
| Molar mass | 506.658 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase.[1] Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.
Function
Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumor cells, leading to aggressive metastatic cancers.[2] In addition, BGB324 enhances sensitivity to various therapies including chemotherapy, immunotherapy and several targeted therapeutics.[3][4]
Clinical trials
Bemcentinib is currently undergoing Phase II clinical trials for non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), acute myeloid leukemia /myelodysplastic syndrome (AML/MDS), melanoma and metastatic pancreatic cancer.[citation needed]
COVID-19
In April 2020 Bemcentinib became the first candidate to be selected as part of the UK Government's ACCORD (Accelerating COVID-19 Research & Development) for Phase II clinical trial in patients with COVID-19.[5]
References
- ↑ "Definition of AXL inhibitor BGB324". NCI Drug Dictionary. National Cancer Institute. 2011-02-02. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=771720.
- ↑ Gay, Carl M; Balaji, Kavitha; Byers, Lauren Averett (2017). "Giving AXL the axe: targeting AXL in human malignancy". British Journal of Cancer. 116 (4): 415–423.
- ↑ "The role of Axl receptor tyrosine kinase in tumor cell plasticity and therapy resistance.". Biomarkers of the Tumor Microenvironment. Springer, Cham.. 2017. pp. 351–376.
- ↑ "Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy". Frontiers in Pharmacology 8: 970. 2018. doi:10.3389/fphar.2017.00970. PMID 29375377.
- ↑ "BerGenBio's Bemcentinib Selected to be Fast-tracked as Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative". https://www.prnewswire.co.uk/news-releases/bergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html.
 |  |
